ReviewFrontiers in pharmacology2026
A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease (IHD) is one of the major cardiovascular disorders leading to global morbidity and mortality and represents a huge burden on individuals and the healthcare system worldwide. Classically, it is attributed to obstructive atherosclerotic plaques in the epicardial coronary arteries; however, it is now understood to be a heterogeneous disease that also includes microvascular dysfunction, vasospasm, and ischemia with non-obstructive coronary arteries (INOCA). IHD is triggered by modifiable and non-modifiable risk factors, and its diagnosis relies on clinical assessment, electrocardiography, cardiac biomarkers, and advanced imaging techniques. Extensive investigations and trials have established the management of IHD, including lifestyle modifications, pharmacological therapies, and revascularization, while novel interventional, regenerative, and molecularly targeted therapies are under active investigation. This review provides a comprehensive overview of IHD, integrating its epidemiology, risk factors, pathophysiology, diagnostics, and therapeutics. IHD pathogenesis is complex, involving coronary atherosclerosis, plaque disruption, thrombosis, and myocardial ischemia-reperfusion injury that are modulated by oxidative stress, inflammation, and other signaling pathways. The review also addresses the molecular mechanisms and therapeutic potential of natural bioactive compounds, including polyphenols, terpenoids, and alkaloids, which exhibit antioxidant, anti-inflammatory, and cardioprotective effects. In addition, it highlights the multifaceted nature of IHD and underscores the need for integrated, mechanism-driven approaches to improve prevention, early detection, and personalized treatment for this global health burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.